Delphi Panel on the Recommended Use of the Cue COVID-19 at Home Diagnostic Test


Tsay D1, Pastor L2, Whitney S3, Bourque M2, Duggal N4
1Cue Health, San Diego, CA, USA, 2Eversana, Burlington, ON, Canada, 3Eversana, Oakville, ON, Canada, 4Cue Health, Dublin, CA, USA

Presentation Documents

OBJECTIVES: The Cue COVID-19 test is an at-home molecular nucleic acid amplification test (NAAT) that detects the RNA of SARS-CoV-2 using a nasal swab sample, with an accuracy rate of 98.9%. This study aims to understand how clinicians who treat immunocompromised (IC) patients view the Cue COVID-19 test, how the Cue COVID-19 test compares to other COVID-19 tests, and the types of IC patients who would benefit from access to Cue COVID-19 tests.

METHODS: Data for the study were collected using a modified Delphi panel methodology. Two sets of electronic surveys were administered in fall 2022 eliciting the opinions of expert panelists on the value of the Cue COVID-19 test, the IC patient population who should be regularly tested for COVID-19, and recommendations on when and how these patients may be tested. Consensus rules were defined a priori; consensus was defined as agreement by ≥ 75% of the panelists.

RESULTS: Expert opinions were anonymously collected from eight oncologists/ hematologists/ immunologists with extensive experience treating IC patients in the US. Consensus was achieved that the Cue COVID-19 test would provide value to all IC patients, and that they would benefit from access to this at-home test. Particularly, the panelists agreed that patients would benefit if they were symptomatic, exposed to COVID-19, undergoing chemotherapy, or have HIV with low CD4 count. Panelists recommended that patients should have access to between 1 and 6 Cue COVID-19 tests per month (average of 2.5 tests/month).

CONCLUSIONS: The study aims to understand the value of the Cue COVID-19 test for IC patients. Clinicians included on this panel agreed that the Cue COVID-19 test would provide value to IC patients, and that IC patients should have access to between 1 and 6 tests per month (average of 2.5 tests/month), for particular use when symptomatic, exposed to COVID-19, or while undergoing chemotherapy.

Conference/Value in Health Info

2023-05, ISPOR 2023, Boston, MA, USA

Value in Health, Volume 26, Issue 6, S2 (June 2023)




Medical Technologies, Study Approaches

Topic Subcategory

Diagnostics & Imaging, Surveys & Expert Panels


No Additional Disease & Conditions/Specialized Treatment Areas

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now